AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Company details clinical development plan for CG53135 and CR002.
2004 DEC 1 - (NewsRx.com & NewsRx.net) -- CuraGen Corp. (CRGN) announced progress with their pipeline of protein, antibody, and small-molecule therapeutics highlighted by the transitioning of CG53135 into phase II for the prevention of oral mucositis (OM) in cancer patients undergoing bone marrow transplantation (BMT).
The company also announced that CR002, a fully human monoclonal antibody, is being developed for the treatment of IgA nephropathy and will begin a phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy male volunteers.
"We are very pleased to transition CG53135 into phase II and bring CR002 into a phase I program. CuraGen has focused its resources on advancing CG53135 for both the prevention and treatment of oral mucositis, CR002 for IgA nephropathy, and PXD101 for solid and hematologic cancers, through clinical development," stated Timothy M. Shannon, MD, executive vice president research and development and chief medical officer. "We are also very excited about CR011, a potential treatment for metastatic melanoma, which we anticipate will enter the clinic during the first half of 2006."
CG53135 is a novel growth factor discovered by CuraGen that promotes both epithelial and mesenchymal cell proliferation in vitro and is active in animal models of OM. Safety, tolerability, and activity results from the phase I program with CG53135 will be presented at the 46th annual meeting of the American Society of Hematology in December. The goal of this phase II clinical trial is to establish, in a randomized, controlled trial, the safety and efficacy of a single dose of CG53135, compared to a placebo, in preventing the development of clinically significant OM in cancer patients undergoing BMT.
The trial will be conducted at ...
- Alliance to develop oral treatment for IgA-nephropathy.
- Newspaper article from: Biotech Week March 24, 2004 700+ words
...IgA-nephropathy. IgA-nephropathy is a disorder that...oral treatment for IgA-nephropathy. "This alliance...cooperation." Nefecon is a clinical development of a new method for treatment for IgA-nephropathy. The method of treatment...
- West Pharmaceutical Services, Inc. and Pharmalink AB Forge Alliance to...
- Press release article from: Business Wire February 23, 2004 700+ words
...for the treatment of IgA-nephropathy, a disorder that...oral treatment for IgA-nephropathy. "This alliance...Nefecon(TM) is a clinical development of a new method for treatment for IgA-nephropathy. The method of treatment...
- BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme...
- Press release article from: PR Newswire December 3, 2007 700+ words
...IgA protease for treating IgA nephropathy. IgA proteases have been...deposition of which causes IgA nephropathy, an orphan kidney disorder...develop ESRD caused by IgA nephropathy out of the 40,000 patients...is currently in Phase 2 clinical development for the ...
- Primary IgA Nephropathy: Pathophysiology, Diagnosis, and Clinical Management.
- Magazine article from: Nephrology Nursing Journal Staples, Betsy Jane April 1, 2001 700+ words
Immunoglobulin A (IgA) nephropathy was first described in 1968...Cohen, & Adler, 1996). IgA nephropathy, or Berger's disease, is...blacks (Emancipator, 1998). IgA nephropathy usually occurs in the second...
- Pulmonary capillaritis in IgA nephropathy.
- Magazine article from: Southern Medical Journal Anantham, Devanand Chan, Kenneth P.W. Chuah, Khoon Leong Vathsala, Anantharaman Eng, Philip June 1, 2007 700+ words
...rare manifestation in patients with IgA nephropathy. A 20-year-old male with hemodialysis...renal and pulmonary manifestations of IgA nephropathy and the management of the resultant...capillaritis, diffuse alveolar hemorrhage, IgA nephropathy ********** Pulmonary capillaritis...
- IgA nephropathy associated with X-linked thrombocytopenia.
- Newspaper article from: Drug Week June 11, 2004 700+ words
...NewsRx.com & NewsRx.net) -- IgA nephropathy is associated with X-linked thrombocytopenia...He developed immunoglobulin A (IgA) nephropathy at the age of 4 years." "Genetic...stage renal failure as a result of IgA nephropathy. The maternal uncle was inferred...
- Inulin: IgA nephropathy (first report) and anaphylaxis in a child: case report
- Magazine article from: Reactions Weekly Anonymous October 11, 2008 700+ words
...year-old boy developed relapse of IgA nephropathy and anaphylaxis during treatment with...38 mg/dL. Renal biopsy revealed IgA nephropathy with endo- and extracapillary proliferation...biopsy, which revealed a relapse of IgA nephropathy. He had severe glomerular damage...
- CuraGen Receives Orphan Drug Designation from the FDA for CR002 in IgA...
- Press release article from: PR Newswire November 11, 2004 700+ words
...treatment to slow the progression of IgA nephropathy and delay kidney failure in patients...prevent kidney failure in patients with IgA nephropathy has the potential to improve patient...is involved in the pathogenesis." IgA nephropathy is a chronic kidney condition estimated...
Source: HighBeam Research, Company details clinical development plan for CG53135 and CR002.